Jessica Gobbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jessica Gobbo has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Garrido
FIBAO, Complejo Hospitalario de Jaén, Jaén, Spain
5 shared publications Aurélie Bertaut
Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, CTRDS, Dijon, France
3 shared publicationsMarine Cordonnier
Laboratoire d'Excellence LipSTIC, UMR 1231, INSERM, Dijon, France
3 shared publications- Valentin Vautrot
Université Bourgogne Europe, CHU Dijon Bourgogne, Centre de recherche Translationnelle en Médecine moléculaire – Inserm UMR1231 équipe GAD, Dijon, France
3 shared publications Carmen Garrido
INSERM 1231, CTM, HSP‐pathies, Label “Ligue National contre le Cancer” and Label d'Excellence LipSTIC Dijon France
2 shared publicationsCharlée Nardin
Department of Dermatology University Hospital of Besançon Besancon France
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Springer Nature in BMC Cancer
Predicting response to anti-PD-(L)1 therapies using plasma-derived extracellular vesicles in NSCLC and advanced melanoma: protocol for a prospective multicenter cohort study
Background: Immune checkpoint inhibitors (ICIs), including anti-programmed cell death-1/programmed death ligand-1 (anti-PD-(L)1) therapies, have improved outcomes in patients with advanced non-small cell lung cancer (NSCLC) and melanoma. However, objective response rates remain limited (40 to 60%), and existing biomarkers, including tumor PD-L1 expression and emerging markers such as tumor mutational burden (TMB) and circulating tumor DNA (ctDNA) dynamics, remain insufficient to accurately predict response to ICIs. Extracellular vesicles (EVs), carrying proteins and nucleic acids originating from tumor and immune cells, represent a promising minimally invasive source of biomarkers reflecting both tumor biology and systemic immune status. We previously identified an EV-associated signature linked to response to anti-PD-(L)1 therapy in a small cohort of patients with NSCLC or melanoma, supporting its further validation in larger prospective cohorts. Methods: EVpredict is a prospective, multicenter, non-randomized study designed to evaluate the predictive value of EV-associated immune and tumor biomarkers in patients with unresectable locally advanced or metastatic NSCLC or melanoma treated with anti-PD-(L)1 therapies. A total of 378 patients will be enrolled. Blood samples will be collected longitudinally before and during anti-PD-(L)1 treatment. EVs will be isolated from plasma and characterized by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and EV marker profiling, following MISEV2023 guidelines. EV-associated proteins will be quantified by multiplex ELISA, while EV-derived miRNAs will be analyzed by small RNA sequencing and RT-qPCR. The primary objective is to determine the association between baseline EV protein biomarkers and treatment response, assessed by best overall response (BOR) according to RECIST 1.1 criteria within 6 months. Secondary objectives include the identification of an EV-derived miRNA predictive signature, predictive score development, evaluation of longitudinal changes in EV-associated biomarkers during follow-up, assessment of their predictive value for primary and secondary resistance and progression-free survival (PFS), and comparison with current standard biomarkers. Discussion: This study aims to validate EV-associated multimolecular signatures as predictive biomarkers of anti-PD-(L)1 response. Strengths include prospective multicenter recruitment, standardized sampling, centralized processing, and minimally invasive longitudinal monitoring. If validated, EV-derived signatures could improve patient stratification and support more personalized immunotherapy strategies. Trial registration: ClinicalTrials.gov identifier NCT07376512. Registered 29 January 2026, https://clinicaltrials.gov/study/NCT07376512?term=evpredict&viewType=Card&rank=1
- 6 November 2026
- Published by Springer Nature in BMC Cancer
Open AccessPredicting response to anti-PD-(L)1 therapies using plasma-derived extracellular vesicles in NSCLC and advanced melanoma: protocol for a prospective multicenter cohort study
Background: Immune checkpoint inhibitors (ICIs), including anti-programmed cell death-1/programmed death ligand-1 (anti-PD-(L)1) therapies, have improved outcomes in patients with advanced non-small cell lung cancer (NSCLC) and melanoma. However, objective response rates remain limited (40 to 60%), and existing biomarkers, including tumor PD-L1 expression and emerging markers such as tumor mutational burden (TMB) and circulating tumor DNA (ctDNA) dynamics, remain insufficient to accurately predict response to ICIs. Extracellular vesicles (EVs), carrying proteins and nucleic acids originating from tumor and immune cells, represent a promising minimally invasive source of biomarkers reflecting both tumor biology and systemic immune status. We previously identified an EV-associated signature linked to response to anti-PD-(L)1 therapy in a small cohort of patients with NSCLC or melanoma, supporting its further validation in larger prospective cohorts. Methods: EVpredict is a prospective, multicenter, non-randomized study designed to evaluate the predictive value of EV-associated immune and tumor biomarkers in patients with unresectable locally advanced or metastatic NSCLC or melanoma treated with anti-PD-(L)1 therapies. A total of 378 patients will be enrolled. Blood samples will be collected longitudinally before and during anti-PD-(L)1 treatment. EVs will be isolated from plasma and characterized by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and EV marker profiling, following MISEV2023 guidelines. EV-associated proteins will be quantified by multiplex ELISA, while EV-derived miRNAs will be analyzed by small RNA sequencing and RT-qPCR. The primary objective is to determine the association between baseline EV protein biomarkers and treatment response, assessed by best overall response (BOR) according to RECIST 1.1 criteria within 6 months. Secondary objectives include the identification of an EV-derived miRNA predictive signature, predictive score development, evaluation of longitudinal changes in EV-associated biomarkers during follow-up, assessment of their predictive value for primary and secondary resistance and progression-free survival (PFS), and comparison with current standard biomarkers. Discussion: This study aims to validate EV-associated multimolecular signatures as predictive biomarkers of anti-PD-(L)1 response. Strengths include prospective multicenter recruitment, standardized sampling, centralized processing, and minimally invasive longitudinal monitoring. If validated, EV-derived signatures could improve patient stratification and support more personalized immunotherapy strategies. Trial registration: ClinicalTrials.gov identifier NCT07376512. Registered 29 January 2026, https://clinicaltrials.gov/study/NCT07376512?term=evpredict&viewType=Card&rank=1
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Inhibition de HSP70 : une nouvelle piste thérapeutique contre le cancer
Les HSP ou protéines de stress ont été découvertes chez la drosophile par Ritossa en 1962. Hautement conservées entre les espèces, elles sont essentielles à l’homéostasie cellulaire et plus encore à la survie lors de stress d’origine diverse (chimique, physique, métabolique etc…). Actuellement, chez les mammifères, il existe cinq principales familles d'HSPs en fonction de leur poids moléculaires : HSP110, HSP90, HSP70 et HSP60 et les petites HSPs à laquelle appartient HSP27 (Kampinga et al., 2009). Parmi les HSPs, HSP70 est la plus fortement induite que ce soit par des agressions telles que le stress oxydatif, les agents anticancéreux ou les radiations ionisantes. HSP70 est, contrairement aux cellules « normales », fortement exprimée dans les cellules cancéreuses et confère à ces cellules une résistance aux drogues anticancéreuses (Goloudina, Demidov & Garrido, 2012) favorisant ainsi le développement tumoral. Les propriétés cyto-protectrices de HSP70 ont été jusqu’à présent attribuées par ces fonctions intracellulaires, principalement en inhibant le processus apoptotique à différentes étapes clés de la signalisation cellulaire (Ravagnan et al., 2001). Cependant une forme membranaire de HSP70 a été détectée à la surface des exosomes dérivant des cellules tumorales (Kuppner et al., 2001). HSP70 membranaire participerait au processus de tumorigenèse en inhibant l’activation des cellules myéloïdes suppressives (MDSCs) et en conséquence, la réponse immune anti-tumorale (Pfister et al., 2007; Schmitt, Gehrmann, Brunet, Multhoff, & Garrido, 2007). Par cette double facette, HSP70 représente donc une cible thérapeutique de choix pour la thérapie anticancéreuse. Compte tenu du rôle clé de HSP70, à la fois par ses fonctions intracellulaires et extracellulaires dans le développement tumoral, l’un des projets phare de notre groupe a été de développer des inhibiteurs spécifiques de HSP70, notamment des aptamères peptidiques et des peptides. Dans un premier travail, nous avons démontré in vitro que deux aptamères A8 et A17 (et son dérivé P17), interagissent avec HSP70 sur des domaines différents et sensibilisent les cellules cancéreuses à la mort induite par des agents chimiothérapeutiques. Des études in vivo réalisées chez la souris et le rat confirment ces résultats et mettent en évidence une réduction significative de la croissance tumorale par ces aptamères peptidiques. Dans un deuxième travail, nous avons généré un dérivé de l’aptamère A8, le peptide P8.1. Nous avons démontré que ce peptide est capable de neutraliser la forme membranaire de HSP70, présente à la surface des exosomes, bloquant ainsi l’activation des MDSCs et restaurant la réponse immunitaire anti-tumorale. A plus long terme, ce travail vise à mettre au point et à valider en clinique une thérapie anticancéreuse plus efficace, en associant aux traitements anticancéreux actuels, les inhibiteurs de HSP70.
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Inhibition de HSP70 : une nouvelle piste thérapeutique contre le cancer
Les HSP ou protéines de stress ont été découvertes chez la drosophile par Ritossa en 1962. Hautement conservées entre les espèces, elles sont essentielles à l’homéostasie cellulaire et plus encore à la survie lors de stress d’origine diverse (chimique, physique, métabolique etc…). Actuellement, chez les mammifères, il existe cinq principales familles d'HSPs en fonction de leur poids moléculaires : HSP110, HSP90, HSP70 et HSP60 et les petites HSPs à laquelle appartient HSP27 (Kampinga et al., 2009). Parmi les HSPs, HSP70 est la plus fortement induite que ce soit par des agressions telles que le stress oxydatif, les agents anticancéreux ou les radiations ionisantes. HSP70 est, contrairement aux cellules « normales », fortement exprimée dans les cellules cancéreuses et confère à ces cellules une résistance aux drogues anticancéreuses (Goloudina, Demidov & Garrido, 2012) favorisant ainsi le développement tumoral. Les propriétés cyto-protectrices de HSP70 ont été jusqu’à présent attribuées par ces fonctions intracellulaires, principalement en inhibant le processus apoptotique à différentes étapes clés de la signalisation cellulaire (Ravagnan et al., 2001). Cependant une forme membranaire de HSP70 a été détectée à la surface des exosomes dérivant des cellules tumorales (Kuppner et al., 2001). HSP70 membranaire participerait au processus de tumorigenèse en inhibant l’activation des cellules myéloïdes suppressives (MDSCs) et en conséquence, la réponse immune anti-tumorale (Pfister et al., 2007; Schmitt, Gehrmann, Brunet, Multhoff, & Garrido, 2007). Par cette double facette, HSP70 représente donc une cible thérapeutique de choix pour la thérapie anticancéreuse. Compte tenu du rôle clé de HSP70, à la fois par ses fonctions intracellulaires et extracellulaires dans le développement tumoral, l’un des projets phare de notre groupe a été de développer des inhibiteurs spécifiques de HSP70, notamment des aptamères peptidiques et des peptides. Dans un premier travail, nous avons démontré in vitro que deux aptamères A8 et A17 (et son dérivé P17), interagissent avec HSP70 sur des domaines différents et sensibilisent les cellules cancéreuses à la mort induite par des agents chimiothérapeutiques. Des études in vivo réalisées chez la souris et le rat confirment ces résultats et mettent en évidence une réduction significative de la croissance tumorale par ces aptamères peptidiques. Dans un deuxième travail, nous avons généré un dérivé de l’aptamère A8, le peptide P8.1. Nous avons démontré que ce peptide est capable de neutraliser la forme membranaire de HSP70, présente à la surface des exosomes, bloquant ainsi l’activation des MDSCs et restaurant la réponse immunitaire anti-tumorale. A plus long terme, ce travail vise à mettre au point et à valider en clinique une thérapie anticancéreuse plus efficace, en associant aux traitements anticancéreux actuels, les inhibiteurs de HSP70.
- Open Access
- 22 June 2025
- Published by Wiley in Journal of Extracellular Biology
- Vol. 4 (6) , e70066
Monitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignancy. However, unique immune response patterns can occur, such as pseudoprogression, which corresponds to new lesion development or temporary tumour growth followed by regression. Misidentifying pseudoprogression may halt ICI therapy, due to the absence of biomarkers to distinguish progression from pseudoprogression. In 2020, our team proposed small extracellular vesicles expressing PD‐L1 (sEV‐PD‐L1) as a predictor of melanoma treatment response. We report a case of pseudoprogression in a patient treated with nivolumab and ipilimumab for metastatic melanoma, and showing reduced circulating sEV‐PD‐L1. To our knowledge, this is the first report of PD‐L1 monitoring in circulating sEV during pseudoprogression under ICI. A decrease in PD‐L1 in circulating sEV might be an early sign of disease response to ICI, and may help to diagnose pseudoprogression. This case supports further evaluation of sEV‐PD‐L1 to identify responder patients to ICI, especially in case of pseudoprogression.Trial Registration: EXOMEL1 P/2018/40 1 AC‐2015‐2496/DC‐2014‐2086. NCT05744076.
- 22 June 2025
- Published by Wiley in Journal of Extracellular Biology
- Vol. 4 (6) , e70066
Open AccessMonitoring Pseudoprogression Using Circulating Small Extracellular Vesicles Expressing PD‐L1 in a Melanoma Patient Treated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignancy. However, unique immune response patterns can occur, such as pseudoprogression, which corresponds to new lesion development or temporary tumour growth followed by regression. Misidentifying pseudoprogression may halt ICI therapy, due to the absence of biomarkers to distinguish progression from pseudoprogression. In 2020, our team proposed small extracellular vesicles expressing PD‐L1 (sEV‐PD‐L1) as a predictor of melanoma treatment response. We report a case of pseudoprogression in a patient treated with nivolumab and ipilimumab for metastatic melanoma, and showing reduced circulating sEV‐PD‐L1. To our knowledge, this is the first report of PD‐L1 monitoring in circulating sEV during pseudoprogression under ICI. A decrease in PD‐L1 in circulating sEV might be an early sign of disease response to ICI, and may help to diagnose pseudoprogression. This case supports further evaluation of sEV‐PD‐L1 to identify responder patients to ICI, especially in case of pseudoprogression.Trial Registration: EXOMEL1 P/2018/40 1 AC‐2015‐2496/DC‐2014‐2086. NCT05744076.
- Open Access
- 27 June 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e63718
Small extracellular vesicles as biomarkers in sarcoma follow-up: Protocol for a pilot study (Preprint)
Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death. Currently, metastatic risk assessment relies mainly on histological grading; yet, this method has limitations due to the disease’s heterogeneity. Advances in genomic and transcriptomic research have identified potential molecular signatures, but these approaches lack reproducibility and prognostic reliability. Therefore, new biomarkers are essential for improving risk prediction and therapy adaptation. Recent studies highlight that sarcoma cells secrete extracellular vesicles, particularly small extracellular vesicles (sEVs). These nanovesicles, abundant in bodily fluids such as blood, urine, and saliva, play a crucial role in tumor development, growth, and metastasis. sEVs contain proteins and nucleic acids that mirror tumor characteristics. Given their presence in blood, sEVs offer a promising avenue for noninvasive molecular cancer analysis via liquid biopsy. Preliminary studies in Ewing sarcoma have shown substantial alterations in sEV-derived transcripts, underscoring their potential in tracking disease progression and treatment efficacy. Objective: This study aims to investigate whether sEVs can serve as reliable biomarkers for monitoring sarcoma progression and predicting recurrence risk. Methods: This prospective, multicentric pilot study will enroll adult patients diagnosed with localized or metastatic liposarcomas, leiomyosarcomas, or undifferentiated pleomorphic sarcomas at 3 French cancer centers. The study’s primary goal is to quantify sEVs and analyze their protein and RNA content in the blood of patients with localized or metastatic sarcomas before and after the treatment. sEVs will be isolated from plasma samples, and protein and microRNA concentration will be determined. Research will last, on average, 6 months for patients with localized sarcoma and 4 months for patients with metastatic sarcoma. Results: We expect to identify differences in exosome levels based on disease stage and observe correlations between exosome dynamics and treatment response. If confirmed, these findings could establish sEVs as noninvasive biomarkers for monitoring therapy effectiveness and disease progression in patients with sarcoma. Conclusions: This study could establish a novel, noninvasive biomarker for sarcoma prognosis and treatment monitoring. If successful, a nationwide study will be launched to confirm findings in a larger patient cohort, potentially revolutionizing sarcoma management and improving patient outcomes. Trial Registration: ClinicalTrials.gov NCT03800121; https://clinicaltrials.gov/ct2/show/study/NCT03800121 International Registered Report Identifier (IRRID): DERR1-10.2196/63718
- 27 June 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e63718
Open AccessSmall extracellular vesicles as biomarkers in sarcoma follow-up: Protocol for a pilot study (Preprint)
Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death. Currently, metastatic risk assessment relies mainly on histological grading; yet, this method has limitations due to the disease’s heterogeneity. Advances in genomic and transcriptomic research have identified potential molecular signatures, but these approaches lack reproducibility and prognostic reliability. Therefore, new biomarkers are essential for improving risk prediction and therapy adaptation. Recent studies highlight that sarcoma cells secrete extracellular vesicles, particularly small extracellular vesicles (sEVs). These nanovesicles, abundant in bodily fluids such as blood, urine, and saliva, play a crucial role in tumor development, growth, and metastasis. sEVs contain proteins and nucleic acids that mirror tumor characteristics. Given their presence in blood, sEVs offer a promising avenue for noninvasive molecular cancer analysis via liquid biopsy. Preliminary studies in Ewing sarcoma have shown substantial alterations in sEV-derived transcripts, underscoring their potential in tracking disease progression and treatment efficacy. Objective: This study aims to investigate whether sEVs can serve as reliable biomarkers for monitoring sarcoma progression and predicting recurrence risk. Methods: This prospective, multicentric pilot study will enroll adult patients diagnosed with localized or metastatic liposarcomas, leiomyosarcomas, or undifferentiated pleomorphic sarcomas at 3 French cancer centers. The study’s primary goal is to quantify sEVs and analyze their protein and RNA content in the blood of patients with localized or metastatic sarcomas before and after the treatment. sEVs will be isolated from plasma samples, and protein and microRNA concentration will be determined. Research will last, on average, 6 months for patients with localized sarcoma and 4 months for patients with metastatic sarcoma. Results: We expect to identify differences in exosome levels based on disease stage and observe correlations between exosome dynamics and treatment response. If confirmed, these findings could establish sEVs as noninvasive biomarkers for monitoring therapy effectiveness and disease progression in patients with sarcoma. Conclusions: This study could establish a novel, noninvasive biomarker for sarcoma prognosis and treatment monitoring. If successful, a nationwide study will be launched to confirm findings in a larger patient cohort, potentially revolutionizing sarcoma management and improving patient outcomes. Trial Registration: ClinicalTrials.gov NCT03800121; https://clinicaltrials.gov/ct2/show/study/NCT03800121 International Registered Report Identifier (IRRID): DERR1-10.2196/63718
- Open Access
- 6 January 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-9
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity are defined as tumor non-response which does not allow a good understanding of the diversity of the underlying mechanisms. The main objective of the OncoSNIPE® collaborative clinical research program is to identify early and late markers of resistance to treatment. Multicentric, interventional study with the primary objective to identify early and / or late markers of resistance to treatment, in 600 adult patients with locally advanced or metastatic triple negative or Luminal B breast cancer, non-small-cell lung cancer or pancreatic ductal adenocarcinoma. Patients targeted in this study have all rapid progression of their pathology, making it possible to obtain models for evaluating markers of early and / or late responses over the 2-year period of follow-up, and thus provide the information necessary to understand resistance mechanisms. To explore the phenomena of resistance, during therapeutic response and / or progression of the pathology, we will use a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq), clinical data, medical images and immunological profile by ELISA. Patients will have long-term follow-up with different biological samples, at baseline (blood and biopsy) and at each tumoral evaluation or tumoral progression evaluated by medical imaging. Clinical data will be collected through a dedicated Case Report Form (CRF) and enriched by semantic extraction based on the French ConSoRe (Continuum Soins Recherche) initiative, a dedicated Semantic Clinical Data Warehouse (SCDW) to cancer. The study is sponsored by Oncodesign (Dijon, France) and is currently ongoing. The great diversity of intrinsic or acquired molecular mechanisms involved in resistance to treatment constitutes a real therapeutic issue. Improving understanding of mechanisms of resistance of cancer cells to anti-tumor treatments is therefore a major challenge. The OncoSNIPE cohort will lead to a better understanding of the mechanisms of resistance and will allow to explore new mechanisms of actions and to discover new therapeutic targets or strategies making it possible to circumvent the escape in different types of cancer. Clinicaltrial.gov. Registered 16 September 2020, https://clinicaltrials.gov/ct2/show/NCT04548960?term=oncosnipe&draw=2&rank=1 and ANSM ID RCB 2017-A02018-45.
- 6 January 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-9
Open AccessOncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity are defined as tumor non-response which does not allow a good understanding of the diversity of the underlying mechanisms. The main objective of the OncoSNIPE® collaborative clinical research program is to identify early and late markers of resistance to treatment. Multicentric, interventional study with the primary objective to identify early and / or late markers of resistance to treatment, in 600 adult patients with locally advanced or metastatic triple negative or Luminal B breast cancer, non-small-cell lung cancer or pancreatic ductal adenocarcinoma. Patients targeted in this study have all rapid progression of their pathology, making it possible to obtain models for evaluating markers of early and / or late responses over the 2-year period of follow-up, and thus provide the information necessary to understand resistance mechanisms. To explore the phenomena of resistance, during therapeutic response and / or progression of the pathology, we will use a multidisciplinary approach including high-throughput sequencing (Exome-seq and RNAseq), clinical data, medical images and immunological profile by ELISA. Patients will have long-term follow-up with different biological samples, at baseline (blood and biopsy) and at each tumoral evaluation or tumoral progression evaluated by medical imaging. Clinical data will be collected through a dedicated Case Report Form (CRF) and enriched by semantic extraction based on the French ConSoRe (Continuum Soins Recherche) initiative, a dedicated Semantic Clinical Data Warehouse (SCDW) to cancer. The study is sponsored by Oncodesign (Dijon, France) and is currently ongoing. The great diversity of intrinsic or acquired molecular mechanisms involved in resistance to treatment constitutes a real therapeutic issue. Improving understanding of mechanisms of resistance of cancer cells to anti-tumor treatments is therefore a major challenge. The OncoSNIPE cohort will lead to a better understanding of the mechanisms of resistance and will allow to explore new mechanisms of actions and to discover new therapeutic targets or strategies making it possible to circumvent the escape in different types of cancer. Clinicaltrial.gov. Registered 16 September 2020, https://clinicaltrials.gov/ct2/show/NCT04548960?term=oncosnipe&draw=2&rank=1 and ANSM ID RCB 2017-A02018-45.
- Open Access
Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Recently, immunotherapy has garnered increasing importance in cancer therapy, leading to substantial improvements in patient care and survival. By blocking the immune checkpoints—protein regulators of the immune system—immunotherapy prevents immune tolerance toward tumors and reactivates the immune system, prompting it to fight cancer cell growth and diffusion. A widespread strategy for this is the blockade of the interaction between PD-L1 and PD-1. However, while patients generally respond well to immunotherapy, a certain proportion of patients present tumors that resist these treatments. This portion can be very high in some cancers and hinders cancer curability. For this reason, current efforts are focusing on combining PD-1/PD-L1 immunotherapy with the targeting of other immune checkpoints to counter resistance and achieve better results. Exosomes, small vesicles secreted by almost any cell, including tumor cells, have proven to be key actors in this resistance. The exosomes released by tumor cells spread the immune-suppressive properties of the tumor throughout the tumor microenvironment and participate in establishing metastatic niches. In this review, we will describe immune checkpoints and immune modulators whose presence in tumor-derived exosomes (TEXs) has been established. We will focus on the most promising proteins under scrutiny for use in combination with PD-1 blockade therapy in a clinical setting, such as PD-L1, CTLA-4, TIM-3, CD73/39, LAG-3, and TIGIT. We will explore the immunosuppressive impact of these exosomal proteins on a variety of immune cells. Finally, we will discuss how they can change the game in immunotherapy and guide therapeutic decisions, as well as the current limits of this approach. Depending on the viewpoint, these exosomal proteins may either provide key missing information on tumor growth and resistance mechanisms or they may be the next big challenge to overcome in improving cancer treatment.
Open AccessTumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Recently, immunotherapy has garnered increasing importance in cancer therapy, leading to substantial improvements in patient care and survival. By blocking the immune checkpoints—protein regulators of the immune system—immunotherapy prevents immune tolerance toward tumors and reactivates the immune system, prompting it to fight cancer cell growth and diffusion. A widespread strategy for this is the blockade of the interaction between PD-L1 and PD-1. However, while patients generally respond well to immunotherapy, a certain proportion of patients present tumors that resist these treatments. This portion can be very high in some cancers and hinders cancer curability. For this reason, current efforts are focusing on combining PD-1/PD-L1 immunotherapy with the targeting of other immune checkpoints to counter resistance and achieve better results. Exosomes, small vesicles secreted by almost any cell, including tumor cells, have proven to be key actors in this resistance. The exosomes released by tumor cells spread the immune-suppressive properties of the tumor throughout the tumor microenvironment and participate in establishing metastatic niches. In this review, we will describe immune checkpoints and immune modulators whose presence in tumor-derived exosomes (TEXs) has been established. We will focus on the most promising proteins under scrutiny for use in combination with PD-1 blockade therapy in a clinical setting, such as PD-L1, CTLA-4, TIM-3, CD73/39, LAG-3, and TIGIT. We will explore the immunosuppressive impact of these exosomal proteins on a variety of immune cells. Finally, we will discuss how they can change the game in immunotherapy and guide therapeutic decisions, as well as the current limits of this approach. Depending on the viewpoint, these exosomal proteins may either provide key missing information on tumor growth and resistance mechanisms or they may be the next big challenge to overcome in improving cancer treatment.
- Open Access
- 3 March 2020
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 6 (1) , 1-7
Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study
Background: Cancer is the second leading cause of death globally. Early detection and disease management lead to a better survival rate. Consequently, discovery of novel methods in cancer early diagnosis is a field of active research. Minimally invasive liquid biopsies are generating growing interest. Circulating tumour cells (CTCs) have been identified in patients’ blood; nevertheless, these cells are rare and heterogeneous. Exosomes are extracellular nanovesicles released into the extracellular environment via the endosomal vesicle pathway and found in different body fluids. Exosomes deliver bioactive cargo such as proteins, mRNA and miRNA to recipient cells in the tumour environment. We have recently shown that heat shock protein 70 (HSP70) is detected in the membrane of tumour-derived exosomes, in contrast to normal cells. One single cancer cell can release thousands of HSP70-exosomes, facilitating detection. The aim of the pilot study ExoDiag is to determine whether it is possible to detect and quantify HSP70-exosomes in blood in patients with solid cancers. Methods: Bicentric pilot study that will include 60 adult patients with metastatic and non-metastatic solid tumours and 20 healthy volunteers. Exosomes will be isolated from blood and urine samples, and HSP70 concentration will be determined. Patients will be followed for 1 year. The study is sponsored by Georges-François Leclerc Centre and is currently ongoing. Discussion: We expect to demonstrate that HSP70-exosomes could be a powerful tool to diagnose cancer and to guide clinicians in therapeutic decision-making, improving patient’s care. Trial Registration: ClinicalTrials.gov identifier NCT02662621. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/study/NCT02662621?term=NCT02662621&rank=1
- 3 March 2020
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 6 (1) , 1-7
Open AccessMembrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study
Background: Cancer is the second leading cause of death globally. Early detection and disease management lead to a better survival rate. Consequently, discovery of novel methods in cancer early diagnosis is a field of active research. Minimally invasive liquid biopsies are generating growing interest. Circulating tumour cells (CTCs) have been identified in patients’ blood; nevertheless, these cells are rare and heterogeneous. Exosomes are extracellular nanovesicles released into the extracellular environment via the endosomal vesicle pathway and found in different body fluids. Exosomes deliver bioactive cargo such as proteins, mRNA and miRNA to recipient cells in the tumour environment. We have recently shown that heat shock protein 70 (HSP70) is detected in the membrane of tumour-derived exosomes, in contrast to normal cells. One single cancer cell can release thousands of HSP70-exosomes, facilitating detection. The aim of the pilot study ExoDiag is to determine whether it is possible to detect and quantify HSP70-exosomes in blood in patients with solid cancers. Methods: Bicentric pilot study that will include 60 adult patients with metastatic and non-metastatic solid tumours and 20 healthy volunteers. Exosomes will be isolated from blood and urine samples, and HSP70 concentration will be determined. Patients will be followed for 1 year. The study is sponsored by Georges-François Leclerc Centre and is currently ongoing. Discussion: We expect to demonstrate that HSP70-exosomes could be a powerful tool to diagnose cancer and to guide clinicians in therapeutic decision-making, improving patient’s care. Trial Registration: ClinicalTrials.gov identifier NCT02662621. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/study/NCT02662621?term=NCT02662621&rank=1
- Top Cited PapersOpen Access
- 7 January 2020
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 9 (1) , 1710899
Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients
In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal‐PD‐L1 in melanoma patients’ follow‐up. We studied the dynamics of exosomal‐PD‐L1 from 100 melanoma patients by using an enzyme‐linked immunosorbent assay. We found that PD‐L1 was secreted through exosomes by melanoma cells. Exosomes carrying PD‐L1 had immunosuppressive properties since they were as efficient as the cancer cell from which they derive at inhibiting T‐cell activation. In plasma from melanoma patients, the level of PD‐L1 (n= 30, median 64.26 pg/mL) was significantly higher in exosomes compared to soluble PD‐L1 (n= 30, 0.1 pg/mL). Furthermore, exosomal‐PD‐L1 was detected in all patients whereas only 67% of tumour biopsies were PD‐L1 positive. Although baseline exosomal‐PD‐L1 levels were not associated with clinic‐pathologic characteristics, their variations after the cures (ΔExoPD‐L1) correlated with the tumour response to treatment. A ΔExoPD‐L1 cut‐off of> 100 was defined, yielding an 83% sensitivity, a 70% specificity, a 91% positive predictive value and 54% negative predictive values for disease progression. The use of the cut‐off allowed stratification in two groups of patients statistically different concerning overall survival and progression‐free survival. PD‐L1 levels in circulating exosomes seem to be a more reliable marker than PD‐L1 expression in tumour biopsies. Monitoring of circulating exosomal‐PD‐L1 may be useful to predict the tumour response to treatment and clinical outcome.
- 7 January 2020
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 9 (1) , 1710899
Top Cited PapersOpen AccessTracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients
In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal‐PD‐L1 in melanoma patients’ follow‐up. We studied the dynamics of exosomal‐PD‐L1 from 100 melanoma patients by using an enzyme‐linked immunosorbent assay. We found that PD‐L1 was secreted through exosomes by melanoma cells. Exosomes carrying PD‐L1 had immunosuppressive properties since they were as efficient as the cancer cell from which they derive at inhibiting T‐cell activation. In plasma from melanoma patients, the level of PD‐L1 (n= 30, median 64.26 pg/mL) was significantly higher in exosomes compared to soluble PD‐L1 (n= 30, 0.1 pg/mL). Furthermore, exosomal‐PD‐L1 was detected in all patients whereas only 67% of tumour biopsies were PD‐L1 positive. Although baseline exosomal‐PD‐L1 levels were not associated with clinic‐pathologic characteristics, their variations after the cures (ΔExoPD‐L1) correlated with the tumour response to treatment. A ΔExoPD‐L1 cut‐off of> 100 was defined, yielding an 83% sensitivity, a 70% specificity, a 91% positive predictive value and 54% negative predictive values for disease progression. The use of the cut‐off allowed stratification in two groups of patients statistically different concerning overall survival and progression‐free survival. PD‐L1 levels in circulating exosomes seem to be a more reliable marker than PD‐L1 expression in tumour biopsies. Monitoring of circulating exosomal‐PD‐L1 may be useful to predict the tumour response to treatment and clinical outcome.
- Open Access
- 13 October 2019
- Published by Wiley in Journal of Oncology
- Vol. 2019, 1-18
Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer
Colorectal cancer (CRC) is one of the major causes of cancer-related deaths worldwide. Tumor microenvironment (TME) contains many cell types including stromal cells, immune cells, and endothelial cells. The TME modulation explains the heterogeneity of response to therapy observed in patients. In this context, exosomes are emerging as major contributors in cancer biology. Indeed, exosomes are implicated in tumor proliferation, angiogenesis, invasion, and premetastatic niche formation. They contain bioactive molecules such as proteins, lipids, and RNAs. More recently, many studies on exosomes have focused on miRNAs, small noncoding RNA molecules able to influence protein expression. In this review, we describe miRNAs transported by exosomes in the context of CRC and discuss their influence on TME and their potential as circulating biomarkers. This overview underlines emerging roles for exosomal miRNAs in cancer research for the near future.
- 13 October 2019
- Published by Wiley in Journal of Oncology
- Vol. 2019, 1-18
Open AccessExosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer
Colorectal cancer (CRC) is one of the major causes of cancer-related deaths worldwide. Tumor microenvironment (TME) contains many cell types including stromal cells, immune cells, and endothelial cells. The TME modulation explains the heterogeneity of response to therapy observed in patients. In this context, exosomes are emerging as major contributors in cancer biology. Indeed, exosomes are implicated in tumor proliferation, angiogenesis, invasion, and premetastatic niche formation. They contain bioactive molecules such as proteins, lipids, and RNAs. More recently, many studies on exosomes have focused on miRNAs, small noncoding RNA molecules able to influence protein expression. In this review, we describe miRNAs transported by exosomes in the context of CRC and discuss their influence on TME and their potential as circulating biomarkers. This overview underlines emerging roles for exosomal miRNAs in cancer research for the near future.
- Open Access
- 6 February 2017
- Published by Taylor & Francis in Cell Adhesion & Migration
- Vol. 11 (2) , 151-163
Exosomes in cancer theranostic: Diamonds in the rough
During the last 10 years, exosomes, which are small vesicles of 50–200 nm diameter of endosomal origin, have aroused a great interest in the scientific and clinical community for their roles in intercellular communication in almost all physiological and pathological processes. Most cells can potentially release these nanovesicles that share with the parent cell a similar lipid bilayer with transmembrane proteins and a panel of enclosed soluble proteins such as heat shock proteins and genetic material, thus acting as potential nanoshuttles of biomarkers. Exosomes surface proteins allow their targeting and capture by recipient cells, while the exosomes' content can modify the physiological state of recipient cells. Tumor derived exosomes by interacting with other cells of the tumor microenvironment modulate tumor progression, angiogenic switch, metastasis, and immune escape. Targeting tumor-derived exosomes might be an interesting approach in cancer therapy. Furthermore, because a key issue to improve cancer patients' outcome relies on earlier cancer diagnosis (metastases, as opposed to the primary tumor, are responsible for most cancer deaths) exosomes have been put forward as promising biomarker candidates for cancer diagnosis and prognosis. This review summarizes the roles of exosomes in cancer and clinical interest, focusing on the importance of exosomal heat shock proteins (HSP). The challenges of clinical translation of HSP-exosomes as therapeutic targets and biomarkers for early cancer detection are also discussed.
- 6 February 2017
- Published by Taylor & Francis in Cell Adhesion & Migration
- Vol. 11 (2) , 151-163
Open AccessExosomes in cancer theranostic: Diamonds in the rough
During the last 10 years, exosomes, which are small vesicles of 50–200 nm diameter of endosomal origin, have aroused a great interest in the scientific and clinical community for their roles in intercellular communication in almost all physiological and pathological processes. Most cells can potentially release these nanovesicles that share with the parent cell a similar lipid bilayer with transmembrane proteins and a panel of enclosed soluble proteins such as heat shock proteins and genetic material, thus acting as potential nanoshuttles of biomarkers. Exosomes surface proteins allow their targeting and capture by recipient cells, while the exosomes' content can modify the physiological state of recipient cells. Tumor derived exosomes by interacting with other cells of the tumor microenvironment modulate tumor progression, angiogenic switch, metastasis, and immune escape. Targeting tumor-derived exosomes might be an interesting approach in cancer therapy. Furthermore, because a key issue to improve cancer patients' outcome relies on earlier cancer diagnosis (metastases, as opposed to the primary tumor, are responsible for most cancer deaths) exosomes have been put forward as promising biomarker candidates for cancer diagnosis and prognosis. This review summarizes the roles of exosomes in cancer and clinical interest, focusing on the importance of exosomal heat shock proteins (HSP). The challenges of clinical translation of HSP-exosomes as therapeutic targets and biomarkers for early cancer detection are also discussed.